Quick Answer
NOVAVAX INC reported Operating Income of $452.80 million for fiscal year 2025.
NOVAVAX INC Operating Income — Annual History
| Fiscal Year | Operating Income | YoY Change |
|---|---|---|
| 2025 | $452.80M | +281.9% |
| 2024 | -$248.93M | +56.1% |
| 2023 | -$566.51M | +12.1% |
| 2022 | -$644.74M | +61.8% |
| 2021 | -$1.69B | -304.7% |
| 2020 | -$416.72M | -245.6% |
| 2019 | -$120.58M | +30.7% |
| 2018 | -$173.92M | -1.3% |
| 2017 | -$171.71M | +36.2% |
| 2016 | -$269.11M | -71.2% |
| 2015 | -$157.24M | -87.9% |
| 2014 | -$83.69M | -59.6% |
| 2013 | -$52.43M | -76.8% |
| 2012 | -$29.66M | -37.5% |
| 2011 | -$21.58M | +43.9% |
| 2010 | -$38.49M | -3.0% |
| 2009 | -$37.38M | — |
Quarterly Operating Income
| Quarter Ending | Operating Income | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$178.02M | -32.8% | -276.1% |
| June 30, 2025 | $101.07M | -37.2% | -80.4% |
| March 31, 2025 | $515.51M | +455.9% | +484.7% |
| September 30, 2024 | -$134.02M | -6.7% | -183.2% |
| June 30, 2024 | $161.00M | +190.3% | +211.2% |
| March 31, 2024 | -$144.83M | +53.7% | -15.3% |
| September 30, 2023 | -$125.63M | +1.2% | -326.5% |
| June 30, 2023 | $55.46M | +111.5% | +117.7% |
- NOVAVAX INC showed an increase of +281.9% in Operating Income compared to the prior fiscal year.
- Over the 2009–2025 period, NOVAVAX INC’s operating income has grown by 1311.2% (from -$37.38 million to $452.80 million).
- The most recent figure is from NOVAVAX INC’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 26, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: